Stanford University
Showing 541-550 of 634 Results
-
David Solow-Cordero
Associate Director, High-Throughput Screening, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAssociate Director, High-Throughput Screening Knowledge Center, , Sarafan ChEM-H and Innovative Medicine Accelerator (IMA)
This high-throughput screening (HTS) laboratory allows Stanford researchers and others to discover novel modulators of targets that otherwise would not be practical in industry. The center incorporates instrumentation (purchased with NCRR NIH Instrumentation grant numbers S10RR019513, S10RR026338, S10OD025004, and S10OD026899), databases, compound libraries, and personnel whose previous sole domains were in industry.
Among our instrumentation are a fully automated Molecular Devices ImageXpress Micro Confocal High-Content fluorescence microplate imager, with live cell, fluidics and phase contrast options, an Echo 655 Acoustic Dispense, a Thermo integrated HTS robotic system, a Caliper Life Sciences SciClone ALH3000 and an Agilent Bravo microplate liquid handler, and the BMG Clariostarplus, Tecan Infinite M1000 and M1000 PRO and Molecular Devices FlexStation II 384 fluorescence, luminescence and absorbance multimode microplate readers.
We have over 180,000 small molecules for compound screens, 15,000 cDNAs for genomic screens, and whole genome siRNA libraries targeting the human genome (the siARRAY whole human genome siRNA library from Dharmacon, targeting 21,000 human genes) and the mouse genome (Qiagen mouse whole genome siRNA set V1 against 22,124 genes).
The HTSKC main screening lab is located in ChEM-H W008, the cell-based assay development lab is located in CCSR Room 0133-North Wing, between the Transgenic Mouse Facility, and the Stanford Genomics Facility. -
Scott G. Soltys, MD
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsMy clinical and research interests focus on the development of new radiation techniques involving stereotactic radiosurgery and radiotherapy for the treatment of malignant and benign tumors of the brain and spine, as well as functional disorders such as trigeminal neuralgia.
-
Hong Song, MD, PhD
Assistant Professor of Radiology (Nuclear Medicine)
BioHong Song received his MD from Tulane University School of Medicine and a Ph.D. in Chemical Engineering from Tulane University. He performed research in targeted radionuclide therapy as a postdoctoral fellow at the Johns Hopkins University. Following medical school, he joined Dual pathway Nuclear Medicine and Diagnostic Radiology residency at Stanford. His current research interests include PSMA PET in biochemically recurrent prostate cancer and DOTATATE PET in PRRT for neuroendocrine tumors.
-
Geoffrey Sonn
Professor of Urology
Current Research and Scholarly InterestsMy interest is in improving prostate cancer diagnosis through MRI and image-targeted prostate biopsy. In collaboration with radiologists at Stanford, we are working to define the optimal role of MRI in prostate cancer. We hope to improve cancer imaging to the point that some men with elevated PSA may safely avoid prostate biopsy. For those who need biopsy, we are evaluating novel MRI-US fusion targeted biopsy, a technique that greatly improves upon the conventional biopsy method.
-
David Spiegel
Jack, Lulu and Sam Willson Professor of Medicine
Current Research and Scholarly InterestsDr. Spiegel's research program involves mind/body interactions, including cancer progression, the response to traumatic stress, and the effect of hypnosis on the perception of pain and anxiety.
-
Daniel Spielman
Professor of Radiology (Radiological Sciences Lab) and, by courtesy, of Electrical Engineering
Current Research and Scholarly InterestsMy research interests are in the field of medical imaging, particularly magnetic resonance imaging and in vivo spectroscopy. Current projects include MRI and MRS at high magnetic fields and metabolic imaging using hyperpolarized 13C-labeled MRS.
-
James Spudich
Douglass M. and Nola Leishman Professor of Cardiovascular Disease, Emeritus
Current Research and Scholarly InterestsThe general research interest of this laboratory is the molecular basis of cell motility, with a current emphasis on power output by the human heart. We have three specific research interests, the molecular basis of energy transduction that leads to ATP-driven myosin movement on actin, the biochemical basis of the regulation of actin and myosin interaction and their assembly states, and the roles these proteins play in vivo, in cell movement, changes in cell shape and muscle contraction.
-
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsClinical interests: general oncology, genito-urinary malignancy Research interests: conducting clinical trials in advanced prostate cancer, bladder cancer and renal cell carcinoma
-
Randall Stafford
Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsAs Director of the SPRC Program on Prevention Outcomes and Practices, my work focuses on cardiovascular disease treatment and prevention, the adoption of new technology and practices, and patterns of physician practice, particularly medication prescribing. Specific interests include measuring and improving the quality of outpatient care, disparities in health care by race, gender, age and socioeconomic status, and interventions to improve prevention outcomes.
-
Marcia L. Stefanick, Ph.D.
Professor (Research) of Medicine (Stanford Prevention Research Center), of Obstetrics and Gynecology and, by courtesy, of Epidemiology and Population Health
On Leave from 2026-07-16 To 2027-09-17Current Research and Scholarly InterestsMarcia L. Stefanick, Ph.D is a Professor of Medicine Professor of Obstetrics and Gynecology, and by courtesy, Professor of Epidemiology and Population Health at Stanford University School of Medicine. Dr. Stefanick’s research focuses on chronic disease prevention (particularly, heart disease, breast cancer, osteoporosis, and dementia) in both women and men. She is currently the Principal Investigator the Women’s Health Initiative (WHI) Extension Study, having been the PI of the Stanford Clinical Center of the landmark WHI Clinical Trials and Observational Study since 1994 and Chair of the WHI Steering and Executive Committees from 1998-2011, as well as PI of the WHI Strong and Healthy (WHISH) Trial which is testing the hypothesis that a DHHS-based physical activity intervention, being delivered to a multi-ethnic cohort of about 24,000 WHI participants across the U.S., aged 68-99 when the trial started in 2015, will reduce major cardiovascular events over 8 years, compared to an equal number of “usual activity” controls. Dr. Stefanick is also PI of the Osteoporotic Study of Men (MrOS) which is continuing to conduct clinical assessments of bone and body composition in survivors of an original cohort of nearly 6000 men aged 65 and over in 2001. As founding Director of the Stanford Women’s Health and Sex Differences in Medicine (WHSDM, “wisdom”) Center, she plays a major role in promoting research and teaching on Sex and Gender in Human Physiology and Disease, Women’s Health and Queer Health and Medicine. Dr. Stefanick also plays major leadership roles at the Stanford School of Medicine, including as co-leader of the Population Sciences Program of the Stanford Cancer Institute, Stanford’s NCI-funded comprehensive cancer center.
Dr. Stefanick obtained her B.A. in biology from the University of Pennsylvania, Philadelphia, PA (1974), then pursued her interest in hormone and sex difference research at the Oregon Regional Primate Research Center, after which she obtained her PhD in Physiology at Stanford University, focusing on reproductive physiology and neuroendocrinology, with exercise physiology as a secondary focus. Her commitment to human research led to a post-doctoral fellowship in Cardiovascular Disease Prevention at the Stanford Prevention Research Center, which has been her academic home for nearly 40 years.